<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342341</url>
  </required_header>
  <id_info>
    <org_study_id>Chlorzoxazone</org_study_id>
    <nct_id>NCT01342341</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake</brief_title>
  <official_title>Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goals of this study are to (1) expand knowledge about interactions of&#xD;
      chlorzoxazone with alcohol by assessing the effects of chlorzoxazone compared to placebo in&#xD;
      moderate and heavy social alcohol users and (2) to compare the effects of chlorzoxazone on&#xD;
      visual cue induced alcohol craving to placebo in moderate to heavy social alcohol users.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a 45-day, double-blind, placebo-controlled crossover study in light&#xD;
      to moderate and heavy alcohol users.&#xD;
&#xD;
      The specific aims are to:&#xD;
&#xD;
        1. Determine if chlorzoxazone alters daily alcohol consumption by comparing the mean drinks&#xD;
           consumed per day during chlorzoxazone administration compared with the mean drinks per&#xD;
           day consumed during placebo administration.&#xD;
&#xD;
        2. To determine if polymorphisms in genes encoding for neurotransmitters or receptors&#xD;
           involved in alcohol reward, abuse, dependence, craving, or relapse may predict the level&#xD;
           of response to chlorzoxazone's effects on alcohol consumption or craving.&#xD;
&#xD;
        3. To investigate any change in alcohol craving during a cue induced craving task where&#xD;
           participants view and respond to a number of images.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol Consumption in Drinks/Week.</measure>
    <time_frame>45 days</time_frame>
    <description>Each subject will record how many drinks/week they are consuming while on the study drug and placebo during the 45-day study. The primary outcome of this study is to determine the effect of chlorzoxazone on alcohol consumption. Reduction in alcohol consumption is measured utilizing behavioral inventories, electronic diaries, urine, and ethyl glucuronide.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Parafon Forte first, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then Parafon Forte</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parafon Forte</intervention_name>
    <description>Drug: Parafon Forte administered at study visit&#xD;
Other: Placebo administered at study visit</description>
    <arm_group_label>Parafon Forte first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Parafon Forte</arm_group_label>
    <other_name>Chlorzoxazone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria: Healthy adults who are social drinkers 21 - 50 years of age.&#xD;
&#xD;
          1. Moderate to heavy social drinkers (women=10-25 drinks/week, men=14-30 drinks/week).&#xD;
&#xD;
          2. If female, must be non-lactating, not pregnant, and using a reliable contraception&#xD;
             method (i.e. abstinence, intrauterine device [IUD], or hormonal birth control).&#xD;
&#xD;
          3. Able and willing to provide written informed consent.&#xD;
&#xD;
          4. Able to understand and follow the instructions of the investigator, and understand all&#xD;
             rating scales.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of cocaine, amphetamines, hallucinogens, &quot;ecstasy&quot;, opiates, sedatives, pain&#xD;
             pills, sleeping pills, or other psychoactive drugs more than twice a week.&#xD;
&#xD;
          2. A history of complicated alcohol or other drug withdrawal syndrome(s), e.g. delirium&#xD;
             tremens or seizures.&#xD;
&#xD;
          3. Current physiological dependence on any psychoactive drug (except nicotine or&#xD;
             caffeine) including alcohol, as determined by MD or NP assessment.&#xD;
&#xD;
          4. Current enrollment in an alcohol or other drug treatment program, or current legal&#xD;
             problems relating to alcohol or other drug use, including awaiting trial or&#xD;
             supervision by a parole or probation officer.&#xD;
&#xD;
          5. Currently trying to quit using alcohol and/or &quot;recreational&quot; drugs.&#xD;
&#xD;
          6. Clinically significant medical or psychiatric illness as determined by screening blood&#xD;
             tests, medical history, and physical exam performed or reviewed by the study MD or NP.&#xD;
&#xD;
          7. Bilirubin more than 2 times the normal upper limit.&#xD;
&#xD;
          8. AST (SGOT), ALT (SGPT), or alkaline phosphatase more than 2 Â½ times the normal upper&#xD;
             limit.&#xD;
&#xD;
          9. Symptoms of liver disease, as assessed by MD or NP assessment (jaundice, Hx of&#xD;
             hepatitis, itchy skin, etc.).&#xD;
&#xD;
         10. A current pregnancy, or a woman of child-bearing potential not currently using an&#xD;
             adequate means of contraception.&#xD;
&#xD;
         11. BAC level greater than 0.05% at the beginning of Screening Visit, Visit 1 or Visit 4.&#xD;
&#xD;
         12. Neurological dysfunction or psychiatric disorder severe enough to interfere with&#xD;
             assessment of outcome measures as defined above.&#xD;
&#xD;
         13. Known allergy to chlorzoxazone.&#xD;
&#xD;
         14. Has received an investigational drug within 30 days prior to Study Visit 2 (after&#xD;
             screening visit).&#xD;
&#xD;
         15. Subjects who are unable to read or speak English.&#xD;
&#xD;
         16. Those who, in the opinion of the investigator, are considered unable to adhere to&#xD;
             scheduled appointments, are unlikely to comply with the study protocol, or who are&#xD;
             unsuitable for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Fields, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ernest Gallo Clinic and Research Center</name>
      <address>
        <city>Emeryville</city>
        <state>California</state>
        <zip>94608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <results_first_submitted>April 22, 2014</results_first_submitted>
  <results_first_submitted_qc>May 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2014</results_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorzoxazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Parafon Forte First, Then Placebo</title>
          <description>Participants will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Parafon Forte</title>
          <description>Participants will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Parafon Forte First, Then Placebo</title>
          <description>Participants will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Parafon Forte</title>
          <description>Participants will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Consumption in Drinks/Week.</title>
        <description>Each subject will record how many drinks/week they are consuming while on the study drug and placebo during the 45-day study. The primary outcome of this study is to determine the effect of chlorzoxazone on alcohol consumption. Reduction in alcohol consumption is measured utilizing behavioral inventories, electronic diaries, urine, and ethyl glucuronide.</description>
        <time_frame>45 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Parafon Forte</title>
            <description>Participants received either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo (1st intervention; 14 days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Consumption in Drinks/Week.</title>
          <description>Each subject will record how many drinks/week they are consuming while on the study drug and placebo during the 45-day study. The primary outcome of this study is to determine the effect of chlorzoxazone on alcohol consumption. Reduction in alcohol consumption is measured utilizing behavioral inventories, electronic diaries, urine, and ethyl glucuronide.</description>
          <units>number of drinks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.43" spread="55.65"/>
                    <measurement group_id="O2" value="75.97" spread="42.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment through study completion, up to 45 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Parafon Forte</title>
          <description>This is a cross-over study. Adverse Events Arms/Groups are reported &quot;per intervention&quot;. Group reflects **all** participants who received Parafon Forte intervention during the study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>This is a cross-over study. Adverse Events Arms/Groups are reported &quot;per intervention&quot;. Group reflects **all** participants who received Placebo intervention during the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Mitchell, Clinical Project Director</name_or_title>
      <organization>Ernest Gallo Clinic and Research Center</organization>
      <phone>510-985-3921</phone>
      <email>jmitchell@gallo.ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

